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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not 
viscosupplementation is effective in reducing osteoarthritis knee pain 
 
Study Design: Review of three randomized, double blind, placebo control trials between 2009-
2010 
 
Data Sources: Three randomized, double blind, placebo control trials were found via PubMed 
and NCBI  
 
Outcomes Measured: Each randomized control trial measured knee pain and/or patient 
satisfaction following their intervention (placebo or hyaluronic acid) in patients with knee 
osteoarthritis, which was measured via WOMAC pain scale and patient global assessment forms. 
 
Results: All three randomized studies showed treatment with hyaluronic acid (hylan G-F 20) 
were statistically significant (P<0.05) for change in pain at 14-26 weeks after injection (NNT=6-
8 for Chevalier et al and 4 for Kul-Panza & Berker). Patient satisfaction was higher in the 
experimental groups as compared to the control with conclusions of NNT between 11 and 20 for 
Chevalier et al and Kul-Panza & Berker respectively. Chavelier et al found adverse events such 
as arthralgias and joint effusion in <10% of their study population (NNH=39). No dichotomous 
data was presented in Diacoglu et al; however an ANOVA was deemed statistically significant 
(p<0.01) 
 
Conclusions: Review of these articles concludes that the use of hyaluronic acid is beneficial in 
reducing knee pain and exhibits patient satisfaction. The use of hyaluronic acid needs to be 
evaluated on a case-by-case basis and should not be used in every patient with osteoarthritis, 
particularly if other additional knee injuries or significant surgical history are present.  
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INTRODUCTION 
Osteoarthritis (OA) is a joint disease characterized by degeneration of cartilage with 
damage to the collagen proteoglycan matrix.1 This paper evaluates three double blind, placebo 
controlled, randomized controlled trials (RCTs) comparing the severity of knee pain and patient 
satisfaction in those with osteoarthritis who received viscosupplementation (Hylan G-F 20) 
versus placebo.  
OA is the most common form of arthritis and is in the top 5 leading causes of disability in 
the US.2  The number of adults with osteoarthritis is 51.8 million, 22.1% of the United States 
population.3 In 2009, it was estimated that health care costs for total knee replacements was 
$28.5 billion.2 Furthermore, the cost per patient for OA is ~$5,700 each year.2 There are 11.3 
million visits to physician offices, hospital outpatient facilities and emergency departments every 
year for OA, as reported in 2010.3 The above statistics confirm the importance of providing pain 
relief to patients with OA in efforts to decrease the number of health care visits and expensive 
surgeries, in turn, decreasing health care costs.  
 The exact etiology of osteoarthritis is unknown, but it may be idiopathic or secondary to 
trauma and other medical conditions, such as diabetes, acromegaly, lyme disease, obesity, and 
peripheral neuropathies.1,2 OA results in non-inflammatory pain with common sites being the 
hips, knees, hands, spine, particularly sparing the elbows, wrists and ankles.1,2  The best way to 
evaluate the severity of OA is radiographs.1,2  The radiographic pathology and hallmarks are 
osteophytes, eburnation, joint space narrowing and sclerosis.2   
 First line treatment for OA is acetaminophen with additional treatments including 
NSAIDS, and COX specific NSAIDs with physical therapy.1 Patients also benefit from 
unloading braces for the knee to relieve pressure on the joint space suffering significant cartilage 
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breakdown. Other measures are the use of capsaicin cream, chondroitin and 
viscosupplementation.4 Surgical treatment options include arthroscopy with the definitive 
treatment being a total joint replacement.1   
Total joint replacement requires general anesthesia, immense rehabilitation, risk of 
infection and other post op complications. The use of viscosupplementation injection directly 
into the knee joint has shown to be effective in reducing pain symptoms of osteoarthritis and 
prolong the need for knee replacement. 4-6  Viscosupplementation allows for lubrication of the 
knee joint by replacing the degraded hyaluronic acid in synovial fluid .4-6 Viscosupplementation 
allows the joint to move easily, relieving the pain from the joint grinding bone on bone from 
cartilage degeneration.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
viscosupplementation is effective in reducing osteoarthritis knee pain. 
METHODS 
Middle to older adult men and women with knee osteoarthritis were included in all three 
studies. The intervention was viscosupplementaiton (hylan G-F 20) with a visually matched 
placebo comparison (0.9% saline). The studies measured knee pain and/or patient satisfaction 
following their intervention, using WOMAC pain scale and patient global assessment forms. All 
studies were randomized, double blind, placebo control trials.  
All articles are published in peer-reviewed journals between 2009 and 2010 and 
published in English. Key words used during research via Pubmed and NCBI were 
“viscosupplementation AND osteoarthritis”; “hylan AND patient satisfaction”. The articles 
chosen were based on relevance to the clinical question and presented outcomes as POEMs 
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(patient oriented evidence that matters). Inclusion criteria were RCTs published between 2009-
2010 and exclusions were patients who had secondary arthropathies, trauma, surgeries or recent 
corticosteroid injections. Statistics reported were relative benefit increase (RBI), absolute benefit 
increase (ABI), numbers needed to treat (NNT), relative risk increase (RRI), absolute risk 
increase (ARI), numbers needed to harm (NNH), p-value. Table 1 represents the demographics 
and characteristics of the included studies.  
Table 1: Demographics and Characteristics of Included Studies  
Study Type  #pts Age Inclusion 
Criteria 
External 
Criteria 
W/
D 
Intervention  
Chevalier 
et al 
(2010)4 
Double 
blind 
RCT 
253 >40 y/o -Patients >40 
y/o with 
primary 
osteoarthritis 
knee pain 
criteria  
-OA with 
medial and 
or lateral 
tibiofemoral 
compartment 
-grade II or 
III OA 
 
-secondary OA 
in target knee 
-clinically 
apparent 
effusion in 
affected knee 
-grade IV OA 
-OA of 
contralateral 
knee 
-systemic CS 
in any joint 
within 3 mo 
before 
screening 
21 Single 6mL 
intra-articular 
injection of 
hylan G-F 20 
 
Kul-
Panza & 
Berker 
(2010)5 
Double 
blind 
RCT 
48 Treatment 
group age=  
59.5 ± 8.8 
years  
 
Placebo 
group age= 
62.8 ± 7.8 
years 
 
Men and 
women with 
diagnoses of 
U/L or B/L  
 -grades 1-4 
OA 
No exclusion 
criteria 
reported  
 
3 3 inj of 2 mL 
of 1.5% 
hydraluronate 
sodium intra-
articular 
injection to 
knee with 
osteoarthritis  
(U/L or B/L) 
Diracoglu 
et al 
(2009)6 
Double 
blind 
RCT 
63 Treatment 
group 
age=59.4 ± 
9.9 year 
 
Placebo 
-pts with B/L 
knee 
osteoarthritis 
-stage II or 
III 
-minimum 50 
-pts with co 
arthropathies, -
trauma or 
previous 
surgeries x1 yr 
-pts who 
3 3 intrarticular 
Hylan G-F 20 
(Synvisc ®) 
injections, 1 
week apart   
 
Antonoplos,	hyaluronic	acid	and	OA	4	
group age= 
56.2 ± 7.2 
years 
points from 
VAS scale of 
100mm 
during 
motion  
received HA 
injections past 
6 mo from 
screening 
-pregnancy 
 
OUTCOMES MEASURED 
Outcomes measured included pain level and patient satisfaction following the 
intervention. Chevalier et al4 used the WOMAC pain scale A1-pain while walking for evaluation 
of treatment at week 18 and week 26 following injection. This was measured on a scale of none, 
mild, moderate, severe, extreme4.  Additionally, Chevalier et al4 used a patient global assessment 
and patient pain assessment forms to determine patient satisfaction following treatment. These 
forms evaluated satisfaction on a scale of feeling “very well, well, fair, poor, very poor”.4 
Chevalier et al4  provided adverse events as dichotomous data, reporting the number of 
individuals in both experimental and control groups who experienced arthralgias, joint effusion, 
arthritis, arthropathies, or injection site pain.  
Kul-Panza & Berker5 used a WOMAC scale evaluating pain on walking, climbing stairs, 
pain at night and on sitting, lying, and standing at 14 weeks after injection. Patient satisfaction 14 
weeks after injection was determined via patient questionnaire by feeling “ worse, no change, 
minimal improvement, moderate improvement, very effective”.5  Lastly, Diracoglu et al6 did not 
present dichotomous data, but ran an ANOVA and recorded a p-value for all WOMAC 
parameters as well as resting and activity VAS pain.  
RESULTS 
 Two of the randomized control trials reported dichotomous data, whereas, Diracoglu et 
al6 reported data as continuous. All three studies used hylan GF-20 in the experimental group and 
saline 0.9% in the control group. Chevalier et al4 used one injection of hylan GF-20 for 
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treatment, whereas Diracoglu et al6  used three injections separated by one week and patients in 
Kul-Panza5 received three injections in one week. Kul-Panza & Berker5 reported that their study 
population came from patients who were attending the Physical Medicine and Rehabilitation 
Output Clinic at Marmara University School of Medicine in Istanbul and presented with knee 
pain and a diagnosis of OA.  Chevalier et al4 and Diracoglu et al6 did not report the setting of the 
patient population, but noted that their patients required a diagnoses of OA. The number of 
patients who withdrew from the study were 21 in Chevalier et al4 and 3 patients in both Kul-
Panza &Berker5 and Diracoglu et al6, from a total patient population of 253, 48, and 63 
respectively (Table 1).  
Chevalier et al4 noted that they lost 9 patients from their treatment group and 12 patients 
from the placebo group due to failure to keep on study schedule. Additionally, 1 patient was 
randomly assigned to the treatment group but received the placebo by error and therefore was 
then counted in the placebo group for analysis.4 Diracoglu et al6 reported that 1 patient from the 
placebo group was lost in follow-up due to not benefitting from the treatment, while 2 patients 
from the treatment group were lost in follow-up due to difficulty attending the clinic for 
treatment injections. The 3 patients lost from Kul-Panza5 were due to failure to attend follow-up 
visits. Furthermore, the inclusion and exclusion criteria for the patients in the study are noted in 
Table 1.  
 Table 2 demonstrates the efficacy of hylauronic acid on pain. Chevalier et al4 analyzed 
the WOMAC scales from patients at 18 and 26 weeks after hylan G-F 20 injections. The NNT 
were calculated from the WOMAC criteria, “pain on walking”.4 At 18 weeks, 71% of patients 
from the hylan G-F 20 group (treatment) and 53% of patients from the control group were 
responders.4 Responders were interpreted as those patients reporting a decrease in pain level 
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while walking. This was calculated into a NNT of 6 (Table 2). At 26 weeks, 64% of the patients 
in the experimental group and 50% in the control group were responders, leading to a NNT of  
8.4 The difference between the control and treatment groups was deemed significant by a p-value 
of 0.003 at 18 weeks and 0.028 at 26 weeks.4 This data concluded that 18 weeks would need to 
pass following the treatment of 6 individuals for 1 more patient to see results.4 Furthermore, 26 
weeks would need to pass following the treatment of 8 individuals for 1 more patient to see 
results.4 
 Kul-Panza & Berker5 recorded WOMAC score of walking pain at 14 weeks after 
injections. The percentage of improvement in pain while walking was significantly higher in the 
experimental group (35.2%) compared to the control group (9.1). This was calculated into a 
NNT of 4, meaning that 4 patients would need to be treated with viscosupplementation for 1 
more patient have a decrease in pain when compared to placebo (Table 2). The treatment at 14 
weeks on walking pain was statistically significant in the treatment group over the placebo as 
noted by a p value 0.01 in ANOVA.5 No dichotomous data was reported from Diacoglu et al6 and 
no continuous data was able to be converted to dichotomous. An ANOVA was run and VAS 
pain values as well as all WOMAC parameters except stiffness were significantly lower in the 
treatment group, as noted by a p value of <0.01 (Table 2).6 
Table 2. Efficacy of hyaluronic acid in the treatment of knee osteoarthritis  
Study Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed 
to treat (NNT) 
P-value 
Chevalier et al 
(2010) 4-at 18 
weeks  
34% 18% 6 0.003 
Chevalier et al 
(2010) 4- at 26 
weeks 
28% 14% 8 0.028 
Kul-Panza & 
Berker 
(2010)5 
2.86% 26.1% 4 0.01 
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Diracoglu et al 
(2009)6 
n/a n/a n/a <0.01 
 
Two of the randomized control trials reported dichotomous data on patient satisfaction 
following their treatment intervention.4,5  Chevalier et al4 reported patient global assessment on 
the basis of feeling very well, well, fair, poor, very poor. To determine treatment success, the 
categories “very well, well and fair” were used to calculate NNT. Based on this determination of 
success, 74.2% of patients in the experimental group and 64.4% of patients in the control group 
reported the intervention successful.4 The NNT for patient satisfaction was then calculated to be 
11 (Table 3). Kul-Panza & Berker5 reported patient satisfaction as either no change from 
baseline, minimal improvement, moderate improvement, or very effective. Included in the 
calculation for NNT were the categories “minimal improvement, moderate improvement, and 
very effective”. This correlated to a reported 87% patient satisfaction in the treatment group 
compared to an 82% in the control group.5 The NNT was calculated to be 20 (Table 3). Of these 
results, it is concluded that for 1 more patient to find the treatment successful, between 11 and 20 
patients would need to be treated.  
Table 3. Efficacy of hylauronic acid on patient satisfaction of knee OA improvement 
Study Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Numbers needed to 
treat (NNT) 
Chevalier et al 
(2010) 4 at 26 weeks 
15.2% 9.8% 11 
Kul-Panza & Berker 
(2010)5- at 14weeks 
6% 5% 20 
 
Only one randomized trial provided dichotomous data to calculate NNH based on adverse 
events of the treatment. Chevalier et al4 demonstrated that 5.7% of the patients in the 
experimental group experienced some adverse events while 3.1% in the control group. This 
correlates to a NNH of 39, concluding that for every 39 people treated with hylauronic acid, 1 
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more person will experience an adverse event when compared to control (Table 4). The most 
common adverse events were arthralgia, joint effusion, and arthritis with a maximum of 2 
patients in each category reporting such events.4 Adverse events were not reported in Diracoglu 
et al.6 Only 1 patient in the treatment group and control group of Kul-Panza & Berker5 reported 
an adverse, with this event being knee instability.  
Table 4. Adverse events of hyaluronic acid 4 
Adverse reactions Relative risk 
increase 
(RRI) 
Absolute risk 
increase (ARI) 
Numbers 
needed to 
harm (NNH)  
P-value 
Any treatment and/or 
procedure related target 
knee adverse events4 
83.8% 2.6% 39 0.366 
 
DISCUSSION  
The above results suggest a benefit to the use of hyaluronic acid in patients with 
osteoarthritis. The NNT for pain from all three studies are between 4-8 suggesting that you need 
to treat an average of 6 patients in order for 1 more patient to see benefits (Table 2). The NNT 
for patient satisfaction are fairly higher, ranging from 11-20, suggesting that around 15 people 
need to be treated in order to have 1 more patient satisfied with the outcome (Table 3). The NNH 
for Chevalier et al4 was 39, ensuring that a larger number of people can be treated before an 
adverse event occurs (Table 4). Even so, the adverse events reported were not serious and 
consisted of temporary knee issues. 4-6  
There may be a variety of reasons why the NNT for patient satisfaction is higher. Many 
patients want to see immediate results from treatments, especially when pain is involved. 
Hyaluronic acid takes an average of 5 weeks for patients to see improvements in their OA.7,8 The 
product provides relief of symptoms for on average, 6 months.7,8 Even though these global 
assessment forms were given to the patient at least 3 months following the injections, patients 
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may have too high of expectations on joint improvements. Hyaluronic acid is not a definitive 
treatment for OA, and many physicians offering this treatment are prolonging the need for 
invasive options, such as arthroscopy and total joint replacement.1,7  
Hyaluronic acid is only FDA approved for knee osteoarthritis, even though some 
physicians use the injection off label in hips and/or shoulders without insurance coverage to the 
patient.7 Hyaluronic acid comes as brand names Synvisc ® , Orthovisc ®, Hyalgan ® .7 Medicare 
and most insurance companies cover the costs of hyaluronic acid products; however if the 
product is not covered through insurance or it is injected off label, the product can cost up to 
$661 for 5 vials7,8,9  There are no black box warnings for these products but should not be used in 
patients with joint or skin infections, venous stasis or leg edema.8 Particularly for Synvisc ® , 
allergy to feathers, eggs or poultry are a contraindication due to the use of chicken combs in the 
product.8   
There are some limitations in the studies that should be discussed. There was a failure to 
analyze all drop outs, leading to a potential bias in the studies.4-6 A limitation in the efficacy of 
hylauronic acid is noted in Kul-Panza & Berker5 because the study only lasted 3 months, 
therefore no long term effects could be evaluated. Additionally, there was no difference between 
the two group outcomes except at week 14 evaluation of walking pain.5 There is a possible 
placebo effect in all the studies, where the improvement in symptoms may be psychological 
more so than the effect of the actual composition of the injections.4-6 Kul-Panza & Berker5 as 
well as Diracoglu et al6 had relatively small sample sizes of 48 and 63 respectively, compared to 
Chevalier et al4  sample of 253. Lastly, Chevalier et al4 and Kul-Panza & Berker allowed the 
patients to use other analgesics and physical therapy exercise during the course of the study, 
Antonoplos,	hyaluronic	acid	and	OA	10	
while Diracoglu et al6 did not allow any exercise routine nor the use of analgesics. These 
discrepancies may have skewed the results provided in the articles.  
CONCLUSION  
 The results of this review suggest that hyaluronic acid is safe and effective for the use of 
knee osteoarthritis. Even though a NNT could not be calculated for Diracoglu et al6, an ANOVA 
was conducted and therefore a p-value was provided for interpretation of statistical significance. 
The articles showed little adverse events with an NNH of 39 from Chevalier et al4. Statistics 
further show that adverse events occur in <2% of patients who receive hyaluronic injections, 
those events being joint pain and effusion and edema.8 Further research is needed to evaluate the 
efficacy of hyaluronic acid in all joints, with the hope to make the product FDA approved for 
shoulder and hip OA. Further studies should also evaluate patient’s pain and satisfaction at 
multiple time frames, from 1 week after injection to greater than 6 months after injection, in 
efforts demonstrate bell curve in efficacy of the injections overtime. 
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